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ABSTRACT
Following certain types of perinatal or adult-onset brain damage
spasticity is the common feature. A persons's disability can be greatly
increased secondary to spasticity, which may present a major problem
in the restoration of motor function.
Depending on the cause and location of brain injury, the clinical
characteristics of spasticity can vary in signs and severity. These varying
signs include flexor spasms in the patient with the spinal injury, dystonic
posturing in the patient with hemiplegia and spastic diplegia in the child
with cerebral palsy. It is apparent that many factors are involved with
augmented reflexes and the list of possible sources is incomplete.
Spasticity in stroke, spinal cord injury, and traumatic brain injury often
interferes with function, limits independence and can result in secondary
complications such as contractures. Considering the variety of problems
associated with spasticity, it is unlikely that one agent will be beneficial to
all patients. Because it takes normal muscle tone and normal control of
the tone to give rise to normal movement, therapeutic intervention is
often necessary and the type of intervention chosen to
vi

treat a person's spasticity is best individualized for each person.
Two treatment methods currently used are Botox injections and
selective dorsal rhizotomy. The purpose of this study is to review the
literature on Botox injections and selective dorsal rhizotomy in the
treatment of spasticity. This information will hopefully aid therapists in
making decisions as to possible candidates for each type of treatment.
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CHAPTER 1
INTRODUCTION
Following certain types of perinatal or adult - onset brain damage,
spasticity is the common feature. Spasticity is defined as "a motor
disorder characterized by a velocity-dependent increase in tonic stretch
reflexes (muscle tone) with exaggerated tendon jerks, resulting from
hyper- excitability of the stretch reflex, as one component of the upper
motor neuron syndrome."
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A person's disability can be greatly increased secondary to
spasticity, which may present a major problem in the restoration of motor
function.2 Depending on the cause and location of brain injury, the
clinical characteristics of spasticity can vary in signs and severity.3 These
varying signs include flexor spasms in the patient who has a spinal cord
injury, dystonic posturing in the patient who has hemiplegia resulting from
a stroke, and spastic diplegia in the child with cerebral palsy.4 It is
apparent that many factors are involved with augmented reflexes and
the list of possible sources is incomplete.
Spasticity in stroke, spinal cord injury, and traumatic brain injury
often interferes with function, limits independence and can result in
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secondary complications such as contractures. 2 Considering the variety
of problems associated with spasticity, it is unlikely that one agent will be
beneficial to all patients. 4 Because it takes normal muscle tone and
normal control of the tone to give rise to normal movement, therapeutic
intervention is often necessary and the type of intervention chosen to
treat a person's spasticity is best individualized for each person. 5
Two treatment methods currently used to treat spasticity are Botox
injections and selective dorsal rhizotomy. The purpose of this study is to
review current literature on Botox injections and selective dorsal
rhizotomy in the treatment of spasticity. This review will include an
examination of spasticity, a discussion of Botox injections, and a
discussion of selective dorsal rhizotomy. This information will hopefully aid
therapists in making decisions as to possible candidates for each type of
treatment.

CHAPTER 2
SPASTICITY

Before we can understand any type of treatment for spasticity, we
must first try to understand what spasticity is and some of it's causes.
Spasticity is more difficult to characterize than to recognize and still more
difficult to quantify.l One widely accepted definition of spasticity is "a
motor disorder characterized by a velocity-dependent increase in tonic
stretch reflexes (muscle tone) with exaggerated tendon jerks, resulting
from hyperexcitability of the stretch reflex, as one component of the
upper motor neuron syndrome." 6
Spasticity is caused by an injury to upper-motor neurons and
diagnostically it is the hallmark of an upper-motor neuron disorder.1,3
Spasticity is often a common feature following certain types of perinatal
or adult-onset brain damage. 7 Regardless of the age of onset of
damage, accentuated alpha motor neuron discharge is present. Some
of the neurophysiological variables, however, seem to show age-related
differences. Reflex irradiation does not appear to be present following
adult-onset cerebral vascular accident but is present in individuals with
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cerebral palsy.
The clinical characteristics of spasticity can vary in signs and
severity depending on the location and the cause of brain injury.3 There
are four signs of spasticity. Two of the signs, hypertonicity and
hyperactive deep tendon reflexes, must be present in order to diagnose
spasticity while the remaining two signs, clonus and muscle spasms, are
usually, but not always, present in a person experiencing spasticity.
Hypertonicity, also known as increased muscle tone, is an
involuntary resistance to a quick movement or stretch felt in an affected
limb by an examiner.3 The tension between the origin and insertion of
each muscle is referred to as muscle tone. 8 Muscle tone can be defined
as "the sensation of resistance felt as one manipulates a joint through a
range of motion, with the subject attempting to relax."l Muscle tone
consists of several distinct components: 1) physical inertia of the
extremity, 2) mechanical-elastic characteristics of muscular and
connective tissues, and 3) reflex muscle contraction (tonic stretch
reflexes). Hyperactive tonic stretch reflexes are classic components of
spasticity.8 Normal postural tone can be defined as "a state of
readiness." s Muscle tone must be sufficiently high to provide support
against gravity yet low enough to allow a person to move freely.
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Normal movement requires normal muscle tone and normal control of
the tone.
Hyperactive deep tendon reflexes, resulting in a condition referred
to as hyperreflexia, can be seen in individuals with spastic-type cerebral
palsy as an accentuated myotatic (stretch) reflexes. 7 This hyperactive
reflex can also exhibit reflex irradiation where by one muscle group
receives a tendon tap (e.g. quadriceps) and EMG potentials are seen in
that muscle group as well as it's antagonist (Le. hamstrings). Hyperactive
reflexes can also be seen in muscles at sites distant from the point of the
tendon tap. When one has a loss of descending inhibition from higher
centers due to some type of injury, the result can be reflex irradiation.7
To be considered as a positive sign of hyperactive deep tendon reflex,
there must be a decrease in the amount of stimulus needed to elicit a
knee jerk or an exaggerated muscle response. 3
According to Howe and Oldham,5 "clonus is a series of repetitive
muscle contractions elicited by a rapidly applied, but maintained,
stretch."5 Clonus can often be elicited in the patient with spasticity by
quickly initiating and then holding the foot in dorsiflexion. One will see a
rhythmic contraction and partial relaxation of affected muscles in
response to the sustained stretch. 3 Clonus is believed to be the result of
alteration of the normal pattern of motor neuron discharge. 7
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Spasms, according to Webster,9 are "an involuntary and
abnormal contractions of muscle or muscle fibers." Spasms are often in
response to a noxious stimulus. 3 The triggering stimulus is from a visceral
or cutaneous source making spasms unlike the other signs of spasticity
which are triggered only by the stretch of skeletal muscle fibers. It is
important to consider spasms as a sign of spasticity due to the fact that
both spasticity, which is triggered by a muscle stretch, and spasms,
proceeded by noxious stimulus, are often present in the same patient,
although one or the other is usually dominant.3 The spasm can take the
form of sudden flexion or extension. The form demonstrated depends on
several factors, one being the site of the triggering stimulus. Whether
flexion or extension is elicited depends greatly on which would be most
protective to the body. The reflex becomes exaggerated due to lack of
modification of the reflex by higher motor centers. Katz and Rymer!
proposed the idea that changes in the intrinsic muscle mechanical
properties (rather than stretch reflex enhancement) are largely
responsible for spastic hypertonia. These possible neural mechanisms for
spastic hypertonia include increased motor neuronal excitability via
three ways. The first two ways are: 1) excitatory synaptic input is
enhanced and 2) inhibitory synaptic input is reduced. The third way is by
a change in the intrinsic electrical properties of the neuron or secondly
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enhanced stretch-evoked synaptic excitation of motor neurons through
1) hyperactivity of gamma efferent or 2) excitatory interneurons more
sensitive to muscle afferent input. St. George3 proposed that spasticity
occurs when there is lack of control of spinal reflex activity because of
the upper motor neuron damage. It is apparent that many factors are
involved regarding augmented reflexes and the list of possible sources is
incomplete. 1
According to Howe and Oldham,s authors have attempted to
grade spasticity but the quantification of spasticity is a challenging and
difficult problem.1.2 Classification of spasticity has been based primarily
on highly observer-dependent measurements with a concentration on
tabulation of functional activities, biomechanical analysis of limb
resistance to mechanical displacement, purified surface
electromyographic responses to agitation, voluntary movement, gait
analysis and other clinical measurements.1.2 Several systems have been
composed to grade spasticity such as the Modified Ashworth Scale3 and
the Clinical Scale for Spastic Hypertonia. 1 Spasticity is ranked from mild
to severe and the criteria for grading the severity of spasticity are not
standardized, therefore there is no precise method for grading the
severity of spasticity.3 The ability to quantify the presence and severity of
spasticity can be essential to the understanding and treatment of this
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disorder.2 However, since no standardized test of spasticity exists and the
effect of abnormal tone on movement can be clearly seen, it may be
appropriate to substitute a measurement of the 'quality' of movement.5
Measuring the quality of movement can also be valuable in assessing
the effects of a therapeutic interventions such as drug treatments or
surgical procedures? A person's disability can be greatly increased
secondary to spasticity, especially in an incompletely paralyzed person. 8
Spasticity is always present as part of a movement but is never confined
to one muscle group.5 Flexor or adductor spasms may result from a
release of reflexes from descending inhibitory contro!.l For example, a
person with paraplegia may require the use of restraints in his wheelchair
due to severe flexor spasms.
Spasticity presents major problems in the restoration of motor
function and because its presence is so predictable, it is reasonable to
base therapies on the appearance of spasticity.5 "Scissoring" of the
lower extremities may be the result of hip adductor spasms and may limit
a patient's ability to ambulate effectively.l It is also important to realize
when spasticity is beneficial to the patient in carrying out basic activities
of daily living such as transferring. A person with mild spasticity can
trigger extensor spasms in their legs that enables them to stand straight
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while transferring into bed, thus making the transfer easier. 3 Therefore it is
important to note that reduction of spasticity does not necessarily result
in functional gains. 7 For therapeutic interventions, functional gains must
be the goal. It is unlikely that one agent will be beneficial to all patients
considering the variety of problems associated with spasticity. "The
functional impairment due to spasticity must be carefully assessed
before any treatment is considered. 1I4 Therapeutic intervention should
be individualized for each patient and therefore it is important to know
the different options for intervention.

CHAPTER 3
BOTOX INJECTIONS

"Clostridium botulinum" is a bacterium that causes a serious form
of food poisoning. 10 The commercial name for this bacterium is "Botox".
The paralytic neurotoxin has become widely investigated as a potential
therapeutic treatment for a variety or neuromuscular disorders 11 and due
to the fact that in purified form, it is the first bacterial toxin to be used in
medicine. 12 Botox was initially used in the early 1980s to treat
strabismus l2.13 (crossed eye) and blepharospasm l -17 (squinting) and the
Food and Drug Administration (FDA) licensed botulinum toxin as an
oculinum in December 1989 for these two specific eye conditions. 12
Since 1986 18 Botox has also been used to treat spasmodic
dysphonia,11.14.15.17.19.20.21 and is presently used to treat many other
conditions which include spasmodic torticollis,11.15.17.22 cerebral palsy,17.23
dystonia,12.15.24-27 myofascial pain syndrome,26 achalasia,28.29 hemifacial
spasm,11.15.24 and progressive supranuclear palsy.30 Epperson 19 reported
Scott as pioneering the use of botulinum toxin for use as a chemical
denervation of extraocular muscles, resulting in a new area in neurology
10

11
called "interventional neurology."
The bacteria of Clostridium botulinum produces seven 12.19 or
eight15.17.23 serologically distinct toxins that are potent neuroparalytic
agents. The strains of toxin have been identified and labeled A through
G12.15.17.19.23 with the eighth strain distinguished as C_2.15 The bacteria and
spores are harmless, but the toxin produced by the bacteria, when they
grow, are very dangerous. 12 Botulinum toxins are considered the most
poisonous substances known to humankind. 12.15 This anaerobic organism,
sometimes found in improperly canned food is a potentially lethal toxin.20
The food poisoning, due to botulism, blocks the transmission of nerve
impulse to a muscle and this results in muscle weakness, paralysis 10 and
ultimately death.12 Death occurs by suffocation as the botulism
paralyzes the diaphragm and prevents the lungs from functioning. 28
Type A toxin, the most potent known biologic toxin, is easily crystallized
and relatively stable. 17 The toxin is supplied in vials in small amounts
which make the administration of a fatal dose extremely difficult.
In the clinic, when used in minute doses, Botox becomes a very
effective means for relieving spasmodic symptoms. 20 When small doses
of the toxin are injected into the affected muscle,12 it acts
presynaptically at the nerve terminals to prevent calcium dependent 20.30
release of vesicle bound acetycholine. The process is not fully
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understood but the toxin prevents exocytosis of neurotransmitter
vesicles. 1s There are three hypothesized mechanisms a) inhibition of
calcium influx during nerve stimulation, b) induction of calcium ion efflux
and c) direct action of the toxin on acetycholine release at the nerve
terminals. 17 The final outcome is that effective neuromuscular control is
blocked and a functionally denervated muscle results. Focal weakening
and atrophy of the injected muscle is the final result of local Botox
intramuscular injections.
The most effective Botox dose per muscle is not known. 31 For the
treatment of blepharospasm, the recommended dose is 10-30U/eye
whereas for Dysport, another trade name for botulinum toxin, it is 100-200
U/eye. ll The lethal dose for an adult human is estimated at 5,OOOU. 17 In
a study done by Koman et al,17 initial dosage was determined on the
basis of patient body weight and its distribution was based on the
relative mass of the muscle causing deformity. Comella et al 31 showed
improvement was more significant in patients who received
EMG-assisted Botox injections versus clinically assisted injections. The
reason for greater improvements with EMG assistance is believed to be
due to the increased accuracy in identifying overactive muscles.
Koman et al 17 also reported on a protocal where pediatric patients
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received small initial dosages of 1-2U/kg and dosages were increased at
each subsequent follow-up evaluation until the target threshold for the
desired muscle was reached. Threshold was defined as the dose of
Botox necessary to a) eliminate dynamic deformity, b) allow antagonist
muscle(s) to correct the dynamic deformity either partially or
completely, or c) allow effective bracing.
In the literature, there are a number of studies showing the positive
effects of Botox Injections. Polo and Jabbari30 reported a patient with
progressive supranuclear palsy was significantly handicapped by the
degree of his rigidity. After receiving local injections of botulinum toxin in
the upper limb muscles, the patient showed marked improvement and
was able to move his frozen limb. There were a number of studies on the
treatment of dystonia.12.15.24-27 Dystonia is a neurological disorder
characterized by involuntary, sustained, intermittent or repetitive muscle
contractions resulting in abnormal twisting or deviations of posture. 26
After receiving Botox injections, patients with many types of dystonia,
such as blepharospasm, spasmodic torticollis and spasmodic dysphonia,
felt relief when the abnormally contracting muscles were made to relax.
Metzer and Jenkins22 reviewed several studies and reported significant
benefit in 53-90 % of patients with cervical dystonia after Botox injections.
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Even when head control was not dramatically improved, pain
significantly decreased. In the patient who is in the advanced stage of
Parkinson's disease, foot dystonia is frequently observed. 25 The foot
dystonia is often painful and resembles a common muscle spasm. The
pain is probably due to sustained muscle contraction and often
interferes with daily activities. Significant improvement of pain and
dystonia after Botox injections was observed in the study by Pacchetti et
al. 25 Botox injections to lower extremity adductor muscles led to
pronounced improvements in daily toilet care for a patient with multiple
sclerosis and severe adductor spasticity.14
In cerebral palsy, the lesion in the central nervous system often
results in spasticity of various muscle groups.23 Due to the increase in
tone, functional problems develop. The increased tone may also be
responsible for the failure of longitudinal muscle growth which is
characteristic of the condition. Botulinum Toxin-A may have a twofold
benefit to patients with cerebral palsy: 1) reduced levels of hypertonicity
would allow more control of movement for the duration of the toxin's
effect and 2) increased stretch of the relaxed muscle would promote
longitudinal growth, and reduce the incidence of degree of fixed
contractures. In the study done by Miller and Dabney,23 parents
reported that tone was clinically decreased in most patients, with the
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exception of one child who had fixed contractures. Some parents even
reported a gain of maximum range of motion. Koman et al 17 reported
that children with cerebral palsy, who were treated with Botox, showed
noticeable improvements in easing patient care, positioning, and
function. The literature reflects various response times to the Botox
injections with initial change in spasticity seen in as little as three 23 days
and effects lasting up to six months.17.19.20-22
Some of the drawbacks of the use of Botox injection include the
side effects that can occur. The side effects are infrequent and
transient. When used in the treatment of blepharospasm, side effects
have included drooping of the eyelid, blurred vision and double vision,
which ali recovered spontaneously.16 Weakness in the injected muscle is
the principle side effect and can impair useful motor function. 26 Transient
weakness can also occur in nearby muscle due to regional diffusion. For
example, swallowing difficulties have been reported by those patients
being treated for cervical dystonia.32
Injections have to be repeated as symptomatology returns due to
the temporary effect of Botox injections. 20 Muscle recovery occurs when
the muscle develops new extra-junctional acetylcholine receptors. 17.19
New synaptic contacts on the adjacent muscle fiber receptors are
formed when the terminal axon begins to sprout new branches.
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Fast-twitch muscle is functionally denervated longer than slow-twitch
muscle. 17 Effective dosages tend to decrease and the interval between
necessary injections tends to increase with repeated therapy.2o Because
of the repeated injections, 10%12 of patients will develop antibodies to
the toxin. 22•26
There are several advantages of Botox injections over surgical
therapy in the management of intractable diseases. 19 These
advantages include 1) varied degrees of weakening can be achieved
by varying the injected dosages and 2) the patient is awake and
therefore you don't have the risk of anesthesia or postoperative
infection. 19.23
Because Botox has only been used briefly in the clinic, long term
effects are unknown but no lasting side effects have been reported. 13
However, due to the fact that functional nerve sprouts form after each
injection, altering the architecture of muscle innervation, more study is
needed on the effect of repeated injections. 15

CHAPTER 4

SELECTIVE DORSAL RHIZOTOMY
A surgical procedure designed to reduce spasticity is selective
dorsal rhizotomy.33 The term selective refers to the selective sectioning of
segmental rootlets or fascicles with abnormal neurophysiologic
characteristics and sparing of a variable proportion of rootlets with
normal responses. The term rhizotomy is derived from the word rhizomes
which is another term for nerve rootlet.34
According to Walker,34 in 1898, Sherrington rendered cats spastic
by transecting their midbrains. He then severed the posterior nerve roots
of the spinal nerves and the spasticity disappeared, an introduction of
the procedure referred to as selective dorsal rhizotomy. Fifteen years
later, Foerster used the technique to reduce tone in patients with
congenital spastic paraplegia. 35
The reasoning behind selective dorsal rhizotomy is to get a
neurolytic reduction in afferent facilitatory influences on the anterior
horn cell in the patient who demonstrates spasticity and has diminished
inhibitory influences from descending tracts. 36
17
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According to Sweetser et al,37 a revised technique was introduced
into the United States in 1986 which had decreased complications and
has increased the prominence of selective dorsal rhizotomy as a
treatment for spastic cerebral palsy. The revisements have improved the
safety and efficacy of selective dorsal rhizotomy. Peacock and Staudt38
suggested that the principle goal of the surgery is to either improve
functional performance or to ease the daily care routines of the person
with spasticity.
Selective dorsal rhizotomy has been used for both adults and
children with various diagnoses.39 Some of these diagnoses include
patients with multiple sclerosis, spinal cord injuries, myelomeningocele
with tethered cord, and traumatic brain injuries.33 When selective dorsal
rhizotomy has been applied to pediatric populations, it is most
commonly used to treat children with cerebral palsy.
The procedure involves a lumbosacral laminectomy and dural
incision to expose lumbar and sacral spinal nerve roots. 40 Intra operative
electromyography is used to isolate dorsal rootlet bundles associated
with sustained muscular contraction or with diffusion of contractions of
muscle groups not belonging to that nerve's segmental distribution.
Rootlet bundles (containing 3 -5 rootlets) that do not have normal
inhibitory responses to electrical stimulation are sectioned. The rhizotomy
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of the dorsal roots is performed between L2 - S2 but care is taken to
avoid cutting more than two adjacent nerve roots which can cause
excess loss of sensation. 37 Fifty percent or more of rootlets may be
sectioned at a specific root with no detectable loss of cutaneous
sensation in corresponding dermatomes. The S3 and S4 roots are always
avoided at all costs to spare bladder innervation. 33.4 1
The success of selective dorsal rhizotomy depends on the careful
selection of patients. 36 Children with spastic diplegia, who are able to
walk independently and willing to cooperate with the rigorous physical
therapy that will follow the surgery, are considered ideal candidates for
selective dorsal rhizotomy.4o Children with other problems such as rigidity,
dyskinesia or ataxia do not benefit and children with hemiplegia are
considered too mildly involved to benefit.36 Children who have had
insufficient anti-gravity strength to maintain their limb function without
the spasticity in their legs would not be selected as candidates for
selective dorsal rhizotomy for obvious reasons.42 According to
Hendricks,43 selection criteria at the st. Louis Children's Hospital included
diagnoses of spastic diplegia or quadriplegia in patients between the
age of two and twenty-three years of age and no evidence of
significant damage to basal ganglia on magnetic resonance imaging.
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Other selection factors included good muscle strength in the legs and
trunk, history of delayed motor development and motivation and ability
to cooperate in therapy. As mentioned earlier, not all children benefit
from selective dorsal rhizotomy. Individuals who are not candidates for
the procedure include those with a history of meningitis, congenital
infection, head trauma, severe scoliosis and those who would not be
expected to make functional gains after surgery.
According to Goldstein,44 selective dorsal rhizotomy is not usually
performed until a child is at least three years old and more commonly,
seven years old or older. Because the brain cells and the connections in
the brain may change as the child matures, the clinicians often wait until
a child is three years old before identifying the type and severity of his or
her cerebral palsy. In contrast, according to McDonald,33 maximal
functional benefit was shown to occur in preschool age children with
spastic diplegia. This was attributed to the fact that younger patients
may have fewer abnormal movement patterns developed and they
tend to have fewer musculoskeletal deformities.
Surgery always involves some risk, such as infection, unexpected
bleeding, or side effects of anesthesia. 40 The risk that the wrong nerves or
too many nerves will be cut are additional risks of selective dorsal
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rhizotomy. This could result in further complications and can cause new
problems. Intraoperative complications can occur with each child who
undergoes selective dorsal rhizotomy.43 Such complications include
impaired skin integrity related to the surgical incision, immobility or
improper positioning, alteration in comfort related to the surgical incision,
alteration in urinary elimination and neuromuscular changes related to
improper positioning. Even when appropriate nerve rootlets are cut
some children experience sensory abnormalities, such as numbness or
tingling in some areas of the body.40 Serious peri-operative complications
which included bronchospasms, aspiration pneumonia, urinary retention,
sensory loss, cerebrospinal fluid leakage, temporary loss of bowel and
bladder function, spinal subdural hematoma and urinary tract infection
where experienced by some

patients~33.37,41,42,44

Post-operatively, the

patient will experience a great deal of pain for several days.34,40,41.44 There
are several components to the post-operative pain in this patient
population: somatic pain at the operative site, dysaethesia and
hyperaesthesia of the lower extremities, and distress and discomfort
resulting from intermittent muscle spasms of the lower extremities. 40
According to McDonald and Hays,41 severe post-operative pain was
reported in 58% of patients. The effect of dorsal rhizotomy documented
in the literature provides evidence that immediately after surgery
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selective dorsal rhizotomy reduces spasticity and increases joint range of
movement, apparently limited by abnormal muscle tone. 35.40 Gaskill and
Steinbok45 reported decreased spasticity and improved ease of care
taking in non-ambulatory children and improved ambulation in
ambulatory children. Selective dorsal rhizotomy can permanently
reduce spasticity so that the child with spastic cerebral palsy
experiences little or no stiffness, has more normal muscle tone, and
experiences greater ease of movement. 43 Abbott et al 42 noted that all
post selective dorsal rhizotomy groups studied had statistically significant
improvements in the tone of every muscle tested. Goniometric
examination was significantly improved in all joints evaluated. Children
participating in this study experienced dramatic decreases in leg muscle
tone and corresponding improvements in passive range of motion in
their lower extremities one year after surgery. Staudt and Peacock39
stated that functional improvements have been more difficult to
quantify, but rating of gross motor skills has revealed improvements in
developmental postures, transitional movements, and walking abilities.
When improvement occurs, it may be different for each child. 44
Children with spastic diplegia may be able to stand with their feet flat on
the floor, and may also make gains in walking, climbing stairs or self-care
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tasks following selective dorsal rhizotomy. According to Goldstein,44
some report improvement in skills that include upper body movements
which are probably related to an improvement in overall balance and
stability. Improvement in sitting or in the ability to transfer from one
seated position to another has been seen in children with spastic
quadriplegia following selective dorsal rhizotomy. Children may also
improve in self-care skills and be less dependent on the assistance of
others.
According to Goldstein,44 not all children improve after selective
dorsal rhizotomy and some even lose ground. Giuliani35 reviewed
several studies and reported a decrease in strength in the lower limbs
initially following selective dorsal rhizotomy. Strength levels, however,
gradually increased resulting in improved function. Abbott et al 42
reported significant deterioration in plantar flexor ranges, for some
subjects, between six and twelve month examinations. Dudgeon et al 36
stated that some children, who lacked voluntary muscle control or
strength, might have learned to use their spasticity to support upright
stance, sitting or hand placement. After selective dorsal rhizotomy,
retraining may be unsuccessful and therefore result in a loss of function
or difficulty and delay in resuming previous levels of function. McDonald
and Hays41 reported that after three years, 5% of patients had

I
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recurrence of spasticity and an additional 2.5% had recurrence when
followed fifteen years after selective dorsal rhizotomy.
Children with cerebral palsy are at risk of developing a
symptomatic neurogenic bladder.42 Symptoms suggestive of neurogenic
bladder include enuresis, stress incontinence, and dribbling. The
reduction in spasticity following selective dorsal rhizotomy can also result
in a hypotonic bladder requiring intermittent catheterization on either a
temporary or permanent basis. Selective dorsal rhizotomy reduces
spasticity but does not have a direct effect on balance, abnormal
movement patterns, or persistent tonic reflexes. 43 Perhaps the most
important factors influencing outcomes are the child's motivation,
cooperation, and intelligence and the level of family support available
as the child gains new skills. Objective evaluation of treatment outcome
in cerebral palsy remains a challenge. 33 To date, most of the evaluation
of progress after selective dorsal rhizotomy has been subjective in
nature.
Following selective dorsal rhizotomy, weakness, primitive
movement patterns, and impaired motor control persist. 33 For this reason,
intensive therapy appears necessary to maximize ultimate functional
gains. McDonald and Hays41 suggested that intensive and consistent
physical therapy, tailored to the needs of the individual child, is essential
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to ensure maximum physical progress and functional gain during the
postoperative period.
The literature suggests that selective dorsal rhizotomy can be
useful for spasticity in cerebral palsy when patients are carefully
selected. 41 Younger children with spastic diplegia, who are seriously
impaired by spasticity but have retained good selective motor control
and some degree of forward locomotion appear to make the most
functional gains in uncontrolled studies. Pre-operatively, physical
therapists also rule out candidates who have motor impairment due to
dystonia, athetosis, ataxia, and abnormal reflex posturing,34 who would
not be good candidates for the surgical procedure. It is, however, very
difficult to make decisions with absolute confidence regarding who
should receive selective dorsal rhizotomy and therapy.36 Further
clarification is needed to determine which children have the most to
gain from the reduction of spasticity. The long term effects of rhizotomy
have not been documented and questions remain as to whether the
weakening that inherently accompanies rhizotomy will be
counterproductive as age and weight advance. 45

CHAPTER 5
CONCLUSION
Spasticity is very complex and not completely understood.
Physical therapists are often faced with this phenomenon that is
observed in many types of patients. Some patients who often show signs
of spasticity include those who have suffered from spinal cord injuries,
strokes and cerebral palsy. A person's disability may be greatly
increased secondary to spasticity. Depending on the cause, clinical
characteristics may vary in signs and severity. Spasticity may interfere
with function, limit a person's independence and may cause secondary
complications such as contractures.
Although spasticity presents major problems in the restoration of
motor function, it is important to realize that spasticity may be beneficial
in some patients in carrying out basic activities of daily living. Physical
therapists playa vital role in the treatment of spasticity. They will not be
the ones to prescribe Botox injections or selective dorsal rhizotomy but a
therapist's observation can help determine if in fact the spasticity is
disabling or of benefit to the patient.
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When it has been determined that the patient's spasticity is so
severe and is causing multiple complications that interfere with activities
of daily living, medical management will become necessary. Two
options for the treatment of spasticity include Botox injections and
selective dorsal rhizotomy. The choice of treatment will depend on the
severity of the spasticity, the goals to be achieved with spasticity
reduction and criteria for patient selection.
Botox injection therapy is a more conservative treatment form
than selective dorsal rhizotomy. Botox is injected directly into the
affected muscle(s) whereas selective dorsal rhizotomy is a surgical
procedure that requires the cutting of sacral spinal nerve roots.
Unlike Botox, in which effects last temporarily unless use is
continued and/or repeated, selective dorsal rhizotomy is permanent
and irreversible due to nerve rootlet severing. Botox can be used in
patients who exhibit many types of dystonia whereas selective dorsal
rhizotomy is not recommended. Botox can be used in spastic muscles of
the upper and lower extremity and selective dorsal rhizotomy is used
when lower extremity spasticity is problematic.
There are documented side effects with the use of Botox but these
are infrequent and transient. There are also advantages of using Botox
injections over surgical intervention, one of which is that there is no risk
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secondary to the use of anesthesia which is required in selective dorsal
rhizotomy but not with the use of Botox injection.
With selective dorsal rhizotomy, there is risk of cutting too many or
the wrong nerve rootlets, resulting in permanent secondary
complications such as an alteration in urinary elimination. With Botox
injections the most effective dose per muscle is not known and there is
risk of transient weakness in nearby muscles due to regional diffusion.
However, this weakness is only temporary.
Botox use in the clinic has been very limited and long term effects
are unknown. New nerve sprouts form after injection and these sprouts
can alter the architecture of muscle enervation. The consequences
from this require more study. Selective dorsal rhizotomy has been
around for many years and revised techniques have improved upon its
safety and efficacy. However, not all patients improve functionally and
the question remains if the procedure is counterproductive as the age
and weight of the patient advances.
In conclusion, compelling evidence has been presented in the
literature showing that even when spasticity is reduced there may be no
improvement of function. Therapists need to be aware of this and
realize that reducing the tone may increase the range of motion, but
may unmask underlying weakness rather than underlying control.
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